Merck & Co., Inc.
Merck & Co., Inc. is a U.S.-based global health care company focused on prescription medicines, vaccines, and animal health products. Its business is organized into Pharmaceutical and Animal Health, with revenue driven by branded human health therapies and preventive vaccines, plus veterinary medicines, vaccines, and connected animal health solutions.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueHuman health prescription medicines used to treat and prevent disease across oncology, cardiometabolic, respiratory, immunology, virology, and other areas.
Preventive vaccines for pediatric, adolescent, and adult populations sold through health systems, physicians, wholesalers, and governments.
Veterinary medicines, vaccines, and health management solutions for livestock and companion animals.
Customers
Merck sells human health products mainly to drug wholesalers, retailers, hospitals, government agencies, and managed care organizations such as HMOs and PBMs. Its vaccines are purchased by physicians, distributors, wholesalers, and government entities, while Animal Health serves veterinarians, distributors, livestock producers, farmers, and pet owners. Pricing, formulary access, and reimbursement are important because many end customers are intermediated by payers and public programs.
Buy prescription medicines in bulk for downstream distribution and are central to Merck's U.S. channel economics and chargeback/rebate structure.
Purchase or influence access to branded therapies and vaccines through formularies, reimbursement, and contracting decisions.
Buy vaccines and certain medicines through public programs and procurement channels, especially in the U.S. and abroad.
Buy animal health medicines, vaccines, and monitoring solutions to prevent and treat disease in livestock and companion animals.
Purchase selected animal health products through veterinary and retail channels for preventive and therapeutic care.
Strategy
Merck's strategy centers on science-led growth through internal R&D, new product approvals, and external business development. The company is prioritizing oncology, cardiometabolic, respiratory, ophthalmology, and immunology programs while continuing to defend and extend key franchises such as vaccines and animal health. Capital allocation remains balanced between pipeline investment, acquisitions/licensing, dividends, and share repurchases.
Merck needs new products to offset patent expirations, pricing pressure, and declining mature franchises.
External assets can accelerate growth and diversify the portfolio when internal discovery alone is insufficient.
Rebates, chargebacks, formulary placement, and government pricing materially affect realized net sales.
Merck uses operating cash flow to support dividends, repurchases, and strategic investments.
Geography
Q1/2026Merck is a global business with operations across the U.S., Europe, Latin America, the Middle East, Africa, Eastern Europe, and Asia Pacific. The company highlights growth opportunities in developing markets, but those regions also add exposure to currency swings, regulation, and political instability. Manufacturing and development activity is also international, including the Dundalk, Ireland facility acquired in 2025.
Share of the revenue the company reports by geography.
Risks
Merck's biggest risks come from patent expiry, pricing pressure, and dependence on a small number of large products that generate a disproportionate share of profit and cash flow. The company also faces regulatory, litigation, and R&D execution risk, while its global footprint exposes it to FX, tax, geopolitical, and supply-chain issues. In Animal Health, competition and product-cycle risk are similar, but the commercial channels and end markets differ.
- Patent expiration and generic/biosimilar competitionImpact: HighLikelihood: High
Merck relies on patent protection to preserve exclusivity; once lost, sales can fall quickly.
Exposure: Human health and animal health portfolios
- Pricing pressure and formulary accessImpact: HighLikelihood: High
Rebates, chargebacks, government pricing, and managed care negotiations lower realized prices.
Exposure: U.S. prescription medicines and vaccines
- R&D and clinical development failureImpact: HighLikelihood: High
Pipeline assets may not achieve approval or commercial success, leaving gaps after mature products decline.
Exposure - Regulatory and litigation riskImpact: MediumLikelihood: High
Product liability, antitrust, patent disputes, and government investigations can block sales or create charges.
Exposure: Global pharmaceutical operations
- Foreign exchange and geopolitical exposureImpact: MediumLikelihood: High
International sales and operations create volatility from currency moves, local regulation, and political instability.
Exposure
Accounting
Judgemental itemsMerck estimates U.S. and public-sector discounts using channel data and usage assumptions, directly affecting net sales.
Impact: Net revenue and quarterly comparability
Business combinations require fair value estimates for IPR&D, intangibles, and contingent consideration.
Impact: Amortization, impairment risk, and earnings volatility
Licensing deals can create immediate R&D expense or asset recognition depending on structure.
Impact: Period earnings and cash flow timing
Optimization programs and plant actions create charges that affect cost of sales, SG&A, and R&D.
Impact: Operating margin and comparability
Mature products or failed launches can reduce expected cash flows and trigger write-downs.
Impact: Non-cash charges and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Pfizer, Inc
PFE · Pharmaceutical Preparations
Johnson & Johnson
JNJ · Pharmaceutical Preparations
Johnson & Johnson is a U.S.-based healthcare company founded in 1887 that develops, manufactures, and sells products for human health and well-being.
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
Oscar Health, Inc.
OSCR · Hospital & Medical Service Plans
Elanco Animal Health Inc
ELAN · Pharmaceutical Preparations
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Last updated: 24/09/2026